bearish
Ascletis Pharma (歌礼制药) IPO: Valuation Not Justified by Ganovo and Ravidasvir NPV (Part 3)
842 Views23 Jul 2018 17:43
Corrigenda: There is an error in this insight, please note the correction.
Correction: The drug name Conbercept has been misspelt as...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
- Ascletis Pharma (歌礼制药) Post-Listing: Thoughts on Liquidity and Bull Cases06 Aug 2018
- Smartkarma: ECM Coverage Weekly Update (4 August 2018)04 Aug 2018
- BeiGene (百济神州) IPO: Dual-Listing with Upside Capped in the Near Term31 Jul 2018
- Ascletis Pharma (歌礼制药) IPO: Valuation Not Justified by Ganovo and Ravidasvir NPV (Part 3)23 Jul 2018
- Ascletis Pharma (歌礼制药) IPO: Three Valuation Risk Factors (Part 2)23 Jul 2018
- Ascletis Pharma (歌礼制药) IPO: Emerging Player in the Crowded HCV Drug Market16 Jul 2018
x